http://graphics-remarkable.com/about/ Profit Taking Continues With Speculative Biotech Stocks Many of you who trade biopharmaceutical stocks know that $1B may be considered a small cap stock. As we mentioned in yesterday’s post there is weakness in many high flying biotech stocks compared to the larger caps. Today the weakness is more pronounced in many “smaller” cap stocks: […]
http://dreamsystemsdentallab.com/College-and-Highschool Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The bellwether ETF IBB ($211.30) is flat after the index was […]
source url Biopharmaceutical stocks were somewhat mixed today yet we have some nice moves in our portfolio: Alexion (ALXN $125.26) up 7.34% on Q3 Results which showed a 36% increase in sales to $400M and Net Income (GAAP) of $93.8M up from $92.2M in the same quarter of 2012. The Company has $1.3B in cash. A growing pipeline […]
Biotech Stocks Have Recovered From Early October Lows We have been traveling for two weeks and have not posted new content nor made portfolio changes. Despite a significant correction in the biotech sector in early October when major ETFs (IBB) and funds such as the Fidelity Select Biotech Fund (FBIOX) dipped 8-10% briefly from Oct.4-10, […]
Expect to be back by 10/25 in the meantime see previous two posts. Biotech stocks remain choppy. Hold mode with 10% cash. Big action has moved to Internets and new media. See Raynoreport.com for market updates. ________________………… Futures are up almost 1% as of 8:50a EDT 10/10/13 IBB should stabilize well above support of […]
Are Biotech Valuations in the “Bubblet” Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to develop a model going forward that provides valuation metrics for emerging biopharmaceutical companies that have promising pipelines and are ramping […]
Our Indicators Flash a Caution Signal Today No Change in Portfolio Picks If you are not at 10% cash in your biotechnology portfolio it is time to take profits or hedge your portfolio. If your biotech stock did not hit a new high last week you may want to sell it. Risk is rising and […]
Life Science Trading Update 10/4/13 NASDAQ up 0.88% at 3809 Is the market expecting Boehner to settle? Green screen today with most market leaders up about 2%: AMGN, BIIB, PCYC, REGN, VPHM. ETFs up in the 1% range. DX and Tools Movers: GHDX, ILMN. Mid and small-cap biopharmaceuticals: very strong except notable weakness […]
Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less affected by a weaker economy or a dysfunctional government. Moreover momentum is driven by M&A talk, […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.